Dissolution Phenomenon of the Piretanide Amorphous Form Involving Phase Change.

Chikaraishi, Yuji; Otsuka, Makoto; Matsuda, Yoshihisa

doi:10.1248/cpb.44.2111

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

2013

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although extremely important, detailed investigation and analysis into the phase Electronic supplementary material The online version of this article (doi:10.1007/s11095-009-0021-1) contains supplementary material, which is available to authorized users. behavior of pharmaceutical solids during dissolution is very limited (16)(17)(18)(19). In order to prevent crystallization of the amorphous phase, polymers are usually incorporated into the matrix as stabilizers (20)(21)(22)(23).…”

Section: Introductionmentioning

confidence: 99%

Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution

et al. 2010

View full text Add to dashboard Cite

The dissolution advantage of amorphous solids can be negated either by crystallization of the amorphous solid on contact with the dissolution medium or through rapid crystallization of the supersaturated solution. Polymeric additives can potentially retard both of these crystallization routes, leading to the generation of supersaturated solutions that can persist for biologically relevant timeframes.

show abstract